Bibliographic
Year of Publication:
2002
Contact PI Name:
Suzana S. Petanceska
Primary Reference (PubMED ID):
Funding Source:
Alzheimer's Association
Institute for the Study of Aging (ISOA)
Study Goal and Principal Findings:
This preclinical study aimed at testing the effects of Lipitor (atorvastatin) on beta amyloid peptide accumulation in the brains of PSAPP transgenic mice. Data showed that atorvastatin treatment lowered plasma cholesterol, had no effect on brain cholesterol, and attenuated beta amyloid peptide accumulation in brain. The data supported the notion that statin treatment may have value as a preventative therapy for Alzheimer's disease.
Therapeutic Agent
Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
Atorvastatin
Therapeutic Target:
HMG-CoA Reductase
Animal Model
Model Information:
Species:
Mouse
Model Type:
APPxPS1
Model Name:
PS/APP
Strain/Genetic Background:
Not Reported
Experimental Design
Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest
Outcomes
Outcome Measured
Outcome Parameters
Histopathology
beta Amyloid Load
Biochemical
Brain-beta Amyloid Peptide 40
Brain-beta Amyloid Peptide 42
Plasma-Total Cholesterol